Our Take on Recent Reporting on Cigna

Cigna rose 1.3% Friday to $323.9 per share. As reported by Wall Street Journal: "As AbbVie's Humira faces copycat biologics, the biggest beneficiaries will be the middlemen negotiating and dispensing the drugs such as Cigna and CVS." You can read more about it here. For those of you thinking about investing in the stock, here is a brief look at the company's fundamentals.

Cigna Corporation provides insurance and related products and services in the United States. The company belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) ratio of 4.07. In contrast, Cigna has a trailing 12 month P/E ratio of 15.5 and a P/B ratio of 2.2.

Cigna has moved 62.3% over the last year compared to -13.5% for the S&P 500 -- a difference of 75.8%. Cigna has a 52 week high of $331.05 and a 52 week low of $191.74. At today's price of $323.9 per share, Cigna is -8.44% away from its target price of $353.77, and on average, analysts give the stock a rating of buy.1.0% of the company's shares are linked to short positions, and 91.0% of the shares are owned by institutional investors.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.